Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.79 |
| ▸ | GLA | P06280 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.67 |
| ▸ | LMNA | P02545 | 5/20 | 0.67 |
| ▸ | GAA | P10253 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38662807 | 0.92 | ALDH1A1 (0.80) | KMT2AGLAALDH1A1LMNAGAA | |
| SCHEMBL2263678 | 0.89 | KMT2A (0.97) | KMT2AGLAALDH1A1LMNAGAA | |
| SCHEMBL11550121 | 0.88 | KMT2A (1.00) | KMT2AGLAALDH1A1LMNAGAA | |
| SCHEMBL11825700 | 0.84 | KMT2A (0.85) | KMT2AGLAALDH1A1LMNAGAA | |
| SCHEMBL11824360 | 0.82 | LMNA (0.71) | KMT2AGLAALDH1A1LMNAGAA | |
| SCHEMBL5173574 | 0.82 | ALDH1A1 (0.97) | KMT2AGLAALDH1A1LMNAGAA | |
| SCHEMBL1375109 | 0.80 | GLA (0.68) | KMT2AGLAALDH1A1LMNAGAA | |
| SCHEMBL14882056 | 0.79 | ALDH1A1 (0.78) | KMT2AGLAALDH1A1LMNAGAA | |
| SCHEMBL15245693 | 0.79 | KMT2A (0.70) | KMT2AGLAALDH1A1LMNAGAA | |
| SCHEMBL24893050 | 0.78 | KMT2A (0.68) | KMT2AGLAALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275810-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2011-11-10 | — | — | US | disclosed |
| US-7981895-B2 | Histone deacetylase inhibitor; anticancer agents; antiproliferative agents; antitumor agents; psoriasis; piperazine compound containing a carbamic acid group | TOPOTARGET UK LIMITED (GB) | 2011-07-19 | — | — | US | disclosed |
| US-7629343-B2 | Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| US-20080269237-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2008-10-30 | — | — | US | disclosed |
| EP-1492534-B1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LTD (GB) | 2008-06-25 | — | — | EP | disclosed |
| US-20050143385-A1 | Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors | TOPOTARGET UK LIMITED (GB) | 2005-06-30 | — | — | US | disclosed |
| EP-1492534-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TopoTarget UK Limited (GB) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082288-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| US-3933824-A | Piperazinobutyrophenone derivatives | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143385-A1 | Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors | HDAC1, HDAC7, HDAC11 | KMT2A 80/4885GLA 803/4885ALDH1A1 1217/4885 |
| US-20080269237-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | HDAC5, HDAC1, HDAC7 | KMT2A 67/4885GLA 1130/4885ALDH1A1 1221/4885 |
| US-20110275810-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | HDAC5, HDAC1, HDAC7 | KMT2A 67/4885GLA 1130/4885ALDH1A1 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.